1.22
-0.04 (-3.17%)
| Previous Close | 1.26 |
| Open | 1.27 |
| Volume | 130,959 |
| Avg. Volume (3M) | 251,298 |
| Market Cap | 155,241,824 |
| Price / Book | 17.43 |
| 52 Weeks Range | |
| Earnings Date | 23 Jun 2025 - 8 Jul 2025 |
| Diluted EPS (TTM) | -0.110 |
| Total Debt/Equity (MRQ) | 2.69% |
| Current Ratio (MRQ) | 1.02 |
| Operating Cash Flow (TTM) | -1.53 M |
| Levered Free Cash Flow (TTM) | -8.99 M |
| Return on Assets (TTM) | -84.13% |
| Return on Equity (TTM) | -250.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Tiziana Life Sciences Ltd | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 43.06% |
| % Held by Institutions | 2.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Zhang Financial Llc | 31 Dec 2025 | 99,900 |
| Rachor Investment Advisory Services, Llc | 31 Dec 2025 | 17,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |